Safety and efficacy of a new oral contraceptive containing drospirenone
Affiliations
- PMID: 12497672
Item in Clipboard
Safety and efficacy of a new oral contraceptive containing drospirenone
J Reprod Med.
2002 Nov.
Abstract
An oral contraceptive containing ethinyl estradiol and the unique progestin drospirenone provides a new contraceptive option. Ethinyl estradiol is the form of synthetic estrogen used in most oral contraceptives. Drospirenone differs from other synthetic progestins in that it is derived from 17 alpha-spirolactone and is an analogue of spironolactone. The oral contraceptive containing ethinyl estradiol and the unique progestin drospirenone has been shown to be highly efficacious and to provide safety equivalent to that of other oral contraceptive formulations.
Similar articles
-
[Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].Minerva Ginecol. 2007 Aug;59(4):415-25. Minerva Ginecol. 2007. PMID: 17923832 Review. Italian.
-
Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.J Reprod Med. 2002 Nov;47(11 Suppl):985-93. J Reprod Med. 2002. PMID: 12497673 Review.
-
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.Contraception. 2006 Dec;74(6):451-7. doi: 10.1016/j.contraception.2006.07.004. Epub 2006 Sep 27. Contraception. 2006. PMID: 17157101 Clinical Trial.
-
Evolution of progestins. Focus on the novel progestin drospirenone.J Reprod Med. 2002 Nov;47(11 Suppl):975-80. J Reprod Med. 2002. PMID: 12497671 Review.
-
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.Contraception. 2004 Sep;70(3):191-8. doi: 10.1016/j.contraception.2004.05.013. Contraception. 2004. PMID: 15325887 Clinical Trial.